Indian pharma majors are rushing to ‘Make in America’
The Economic Times Jan 19, 2018 US President Donald Trump's 'Make in America' pledge may have spooked many, but Indian pharmaceutical companies are optimistic. Several Indian drugmakers that have large operations in the US are now pushing to acquire assets there by either investing in greenfield manufacturing facilities or through brownfield M&As. Experts told ET that the US tax policy, which slashed tax rates to around 21%, has certain advantages for Indian drug makers. ET has learnt that companies like Sun Pharma BSE -0.74 %, Cadila, Aurobindo and Torrent are looking to acquire manufacturing assets in the US. In an email response, Sun Pharma, India's largest drug maker and the world's fifth largest generic drug maker, said it has an annual capex plan that includes expansion in the West too. "Sun Pharma has an annual capex plan to take care of its growing business in North America, Europe, emerging markets and India. This includes ...